MTVA - MetaVia Inc. Common Stock
| Day | 1m | 10m | 60m | PreMarket | Market | AfterHours | Gap |
|---|---|---|---|---|---|---|---|
| 0.65 0.05 (7.6%) | 0.0 (0.39%) | 0.0 (0.39%) | 0.0 (0.71%) | 0.01 (1.92%) | 0.02 (2.58%) | 0.0 (0.09%) | 0.0 (0.05%) |
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
Category:
PHARMACEUTICAL PREPARATIONS
Market Period:
Market
Earnings & Ratios
- Basic EPS:
- -0.26
- Diluted EPS:
- -0.26
- Basic P/E:
- -2.6908
- Diluted P/E:
- -2.6908
- RSI(14) 1m:
- 88.55
- VWAP:
- 0.7
- RVol:
Events
| Period | Kind | Movement | Occurred At |
|---|